The Journal of the American Medical Association (JAMA) has just reported an interesting shift in end-of-life interventions offered to patients in European Intensive Care units over the past 17 years: withholding life-prolonging therapy and withdrawing of life-prolonging therapy increased by 10% and 14% respectively. The proportion of women patients was roughly the same (about half)